Peptides in the composition of Laennec that show antiviral effects in the therapy of atopic dermatitis and herpes infection
A characteristic feature of atopic dermatitis is herpes infection, which necessitates application of antiviral therapy. The analysis of the peptide composition of Laennec drug by de novo mass spectrometric sequencing allowed us to identify over 10 peptides, characterized by potential antiviral effect at all stages of the viral life cycle. Laennec’s peptides can inhibit viral activation (inhibition of protein HCFC1), fusion of the viral envelope with the plasma membrane in the step of the host cell virus infection (inhibition of protein CD4), virus replication (inhibition of protein CTBP1), maturing of virion (inhibition of proteins CRM1, VPS4B, TPR, proline isomerase), budding of the viral particles from the cell membrane (inhibition of the NEDD4 protein). Laennek therapy in complex treatment of patients with atopic dermatitis and herpes virus infection can be substantiated by its pharmacologic activities including antiviral effect.